Anaplastic Astrocytoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：51頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Anaplastic Astrocytoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Pipeline Review, H1 2014’, provides an overview of the Anaplastic Astrocytoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anaplastic Astrocytoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Astrocytoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Pipeline Review, H1 2014’, provides an overview of the Anaplastic Astrocytoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anaplastic Astrocytoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Astrocytoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaplastic Astrocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Anaplastic Astrocytoma - Overview 7
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 8
Anaplastic Astrocytoma - Therapeutics under Development by Companies 9
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 10
Anaplastic Astrocytoma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Unknown Stage Products 13
Anaplastic Astrocytoma - Products under Development by Companies 14
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 15
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 16
Sanofi 16
Peregrine Pharmaceuticals, Inc. 17
Oncovir, Inc. 18
EirGen Pharma Ltd. 19
Tocagen Inc. 20
Anaplastic Astrocytoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Eir-060 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
leflunomide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Dendritic Cell Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Poly-ICLC - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cotara - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Anaplastic Astrocytoma - Recent Pipeline Updates 43
Anaplastic Astrocytoma - Dormant Projects 46
Anaplastic Astrocytoma - Discontinued Products 47
Anaplastic Astrocytoma - Product Development Milestones 48
Featured News & Press Releases 48
Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen 48
Jan 10, 2012: EirGen Pharma Registers Oncology Product Eir-060 with FDA 48
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 48
Jan 08, 2007: Hana Biosciences Announces 2007 Corporate Goals 49
Jun 09, 2006: Hana Biosciences Receives Orphan Drug Designation For Ropidoxuridine (IPdR), For The Treatment Of Malignant Glioma 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Anaplastic Astrocytoma, H1 2014 7
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Unknown Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Anaplastic Astrocytoma - Pipeline by Sanofi, H1 2014 16
Anaplastic Astrocytoma - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 17
Anaplastic Astrocytoma - Pipeline by Oncovir, Inc., H1 2014 18
Anaplastic Astrocytoma - Pipeline by EirGen Pharma Ltd., H1 2014 19
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Assessment by Combination Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H1 2014 43
Anaplastic Astrocytoma - Dormant Projects, H1 2014 46
Anaplastic Astrocytoma - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Anaplastic Astrocytoma, H1 2014 7
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaplastic Astrocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Anaplastic Astrocytoma - Overview 7
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 8
Anaplastic Astrocytoma - Therapeutics under Development by Companies 9
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 10
Anaplastic Astrocytoma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Unknown Stage Products 13
Anaplastic Astrocytoma - Products under Development by Companies 14
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 15
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 16
Sanofi 16
Peregrine Pharmaceuticals, Inc. 17
Oncovir, Inc. 18
EirGen Pharma Ltd. 19
Tocagen Inc. 20
Anaplastic Astrocytoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Eir-060 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
leflunomide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Dendritic Cell Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Poly-ICLC - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cotara - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Anaplastic Astrocytoma - Recent Pipeline Updates 43
Anaplastic Astrocytoma - Dormant Projects 46
Anaplastic Astrocytoma - Discontinued Products 47
Anaplastic Astrocytoma - Product Development Milestones 48
Featured News & Press Releases 48
Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen 48
Jan 10, 2012: EirGen Pharma Registers Oncology Product Eir-060 with FDA 48
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 48
Jan 08, 2007: Hana Biosciences Announces 2007 Corporate Goals 49
Jun 09, 2006: Hana Biosciences Receives Orphan Drug Designation For Ropidoxuridine (IPdR), For The Treatment Of Malignant Glioma 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Anaplastic Astrocytoma, H1 2014 7
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Unknown Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Anaplastic Astrocytoma - Pipeline by Sanofi, H1 2014 16
Anaplastic Astrocytoma - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 17
Anaplastic Astrocytoma - Pipeline by Oncovir, Inc., H1 2014 18
Anaplastic Astrocytoma - Pipeline by EirGen Pharma Ltd., H1 2014 19
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Assessment by Combination Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H1 2014 43
Anaplastic Astrocytoma - Dormant Projects, H1 2014 46
Anaplastic Astrocytoma - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Anaplastic Astrocytoma, H1 2014 7
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31
